GlassScriptPhysician profile
Gifferd Ko
NPI 1316688526
$3,773.01
in general payments reported to CMS, 2019-2025
13 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what 87% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $126 · 2024: $1,169 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Travel and Lodging: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.07 |
| Travel and Lodging | $1,035.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,543.13 | 2025 | Pico, Collagenase Santyl, Versajet |
| Stryker Corporation | $306.97 | 2024-2025 | Bioskin, Augment Injectable, Graftjacket |
| Kerecis Limited | $273.43 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Paragon 28, INC. | $267.61 | 2024 | Portfolio, Mtp, Silverback |
| Mimedx Group, INC. | $251.69 | 2024-2025 | |
| Medshape, INC. | $190.46 | 2024 | Dynanail |
| Globus Medical, INC. | $167.36 | 2025 | Senza |
| Biocomposites INC | $152.29 | 2024 | |
| Medline Industries LP | $147.79 | 2024 | |
| Integra Lifesciences Corporation | $141.05 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Anika Therapeutics, INC. | $126.31 | 2023 | Toemotion, Tactoset |
| Treace Medical Concepts, INC. | $104.47 | 2024 | |
| United Orthopedics LLC | $100.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gifferd Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.